Premium
2‐Amino‐3‐cyano‐4‐(5‐arylisoxazol‐3‐yl)‐4 H ‐chromenes: Synthesis and In Vitro Cytotoxic Activity
Author(s) -
Akbarzadeh Tahmineh,
Rafinejad Ali,
Mollaghasem Javad Malekian,
Safavi Maliheh,
FallahTafti Asal,
Pordeli Mahboobeh,
Ardestani Sussan Kabudanian,
Shafiee Abbas,
Foroumadi Alireza
Publication year - 2012
Publication title -
archiv der pharmazie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 61
eISSN - 1521-4184
pISSN - 0365-6233
DOI - 10.1002/ardp.201100345
Subject(s) - cytotoxic t cell , chemistry , in vitro , epidermoid carcinoma , doxorubicin , moiety , cell culture , mtt assay , cytotoxicity , neuroblastoma , stereochemistry , nasopharyngeal carcinoma , pharmacology , biochemistry , cancer , biology , medicine , chemotherapy , genetics , radiation therapy
A new series of 4‐aryl‐4 H ‐chromenes bearing a 5‐arylisoxazol‐3‐yl moiety at the C‐4 position were prepared as potential anticancer agents. The in vitro cytotoxic activity of the synthesized compounds was investigated against a panel of tumor cell lines including MCF‐7 (breast cancer), KB (nasopharyngeal epidermoid carcinoma), Hep‐G2 (liver carcinoma), MDA‐MB‐231 (breast cancer), and SKNMC (human neuroblastoma) using the MTT colorimetric assay. Doxorubicin, a well‐known anticancer drug, was used as positive standard drug. Among the synthesized compounds, the 5‐(3‐methylphenyl)isoxazol‐3‐yl analog ( 7j ) showed the most potent cytotoxic activity against all five human tumor cell lines.